FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089638752> ?p ?o ?g. }

• W2089638752 endingPage "77" @default.
• W2089638752 startingPage "70" @default.
• W2089638752 abstract "The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT). Patients received up to 6 28-day cycles of bortezomib 1.3 mg/m², days 1, 4, 8, and 11, plus melphalan 6 mg/m² and prednisone 60 mg/m², days 1-7. After 2-6 cycles, eligible and consenting patients could proceed to ASCT. Responses were assessed by International Uniform Response Criteria. The primary endpoint was complete response (CR) rate with VMP. Forty-five patients were enrolled. Among 44 evaluable patients, response rate was 95%, including 18% ≥CR (9% stringent CR), 27% very good partial responses (VGPR), and 50% partial responses (PR). Twenty patients proceeded to ASCT. Stem cell collection was successful in all; median yield was 5.6×10⁶ CD34⁺ cells/kg. Posttransplant response rates were 30% ≥CR (10% stringent CR), 65% VGPR, and 5% PR. After median follow-up of 14.0/14.6 months, median time to progression and progression-free survival were both 19.8/27.9 months in non-ASCT/ASCT patients. Seven patients have died; 1-year survival rates were 82%/95% in non-ASCT/ASCT patients. The most common grade 3/4 toxicities were thrombocytopenia (20%), neutropenia (28%), and infection (9%). Peripheral neuropathy grade 2-4 was the most common nonhematopoietic side effect occurring 17 patients (38%), although it was typically reversible, and only 5 patients (11%) discontinued therapy as a result of it. Short-course VMP is highly effective and generally well tolerated, both as initial treatment in non-ASCT patients and induction prior to ASCT. VMP did not negatively affect stem cell collection. Longer follow-up and prospective phase III trials are required to validate these initial observations." @default.
• W2089638752 created "2016-06-24" @default.
• W2089638752 creator A5011049554 @default.
• W2089638752 creator A5018462109 @default.
• W2089638752 creator A5018922885 @default.
• W2089638752 creator A5020265434 @default.
• W2089638752 creator A5027756167 @default.
• W2089638752 creator A5034651124 @default.
• W2089638752 creator A5037247107 @default.
• W2089638752 creator A5041503485 @default.
• W2089638752 creator A5044137685 @default.
• W2089638752 creator A5044510471 @default.
• W2089638752 creator A5049055623 @default.
• W2089638752 creator A5056482233 @default.
• W2089638752 creator A5061865992 @default.
• W2089638752 creator A5075225618 @default.
• W2089638752 creator A5078351605 @default.
• W2089638752 creator A5083678047 @default.
• W2089638752 date "2010-01-01" @default.
• W2089638752 modified "2023-09-26" @default.
• W2089638752 title "“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma" @default.
• W2089638752 cites W1938721925 @default.
• W2089638752 cites W1964991829 @default.
• W2089638752 cites W2024123206 @default.
• W2089638752 cites W2044436186 @default.
• W2089638752 cites W2075290032 @default.
• W2089638752 cites W2089294472 @default.
• W2089638752 cites W2096207943 @default.
• W2089638752 cites W2102591890 @default.
• W2089638752 cites W2118820477 @default.
• W2089638752 cites W2119584679 @default.
• W2089638752 cites W2120474651 @default.
• W2089638752 cites W2124560610 @default.
• W2089638752 cites W2142149038 @default.
• W2089638752 cites W2146000276 @default.
• W2089638752 cites W2148672632 @default.
• W2089638752 cites W2152065071 @default.
• W2089638752 cites W2153596485 @default.
• W2089638752 cites W2156708376 @default.
• W2089638752 cites W2156748957 @default.
• W2089638752 cites W2242783700 @default.
• W2089638752 cites W2266446519 @default.
• W2089638752 cites W2521574012 @default.
• W2089638752 cites W2547188540 @default.
• W2089638752 cites W2587824085 @default.
• W2089638752 cites W2594070503 @default.
• W2089638752 cites W2750956955 @default.
• W2089638752 cites W3191009875 @default.
• W2089638752 cites W2333363976 @default.
• W2089638752 doi "https://doi.org/10.1016/j.bbmt.2009.08.017" @default.
• W2089638752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19733251" @default.
• W2089638752 hasPublicationYear "2010" @default.
• W2089638752 type Work @default.
• W2089638752 sameAs 2089638752 @default.
• W2089638752 citedByCount "6" @default.
• W2089638752 countsByYear W20896387522012 @default.
• W2089638752 countsByYear W20896387522013 @default.
• W2089638752 crossrefType "journal-article" @default.
• W2089638752 hasAuthorship W2089638752A5011049554 @default.
• W2089638752 hasAuthorship W2089638752A5018462109 @default.
• W2089638752 hasAuthorship W2089638752A5018922885 @default.
• W2089638752 hasAuthorship W2089638752A5020265434 @default.
• W2089638752 hasAuthorship W2089638752A5027756167 @default.
• W2089638752 hasAuthorship W2089638752A5034651124 @default.
• W2089638752 hasAuthorship W2089638752A5037247107 @default.
• W2089638752 hasAuthorship W2089638752A5041503485 @default.
• W2089638752 hasAuthorship W2089638752A5044137685 @default.
• W2089638752 hasAuthorship W2089638752A5044510471 @default.
• W2089638752 hasAuthorship W2089638752A5049055623 @default.
• W2089638752 hasAuthorship W2089638752A5056482233 @default.
• W2089638752 hasAuthorship W2089638752A5061865992 @default.
• W2089638752 hasAuthorship W2089638752A5075225618 @default.
• W2089638752 hasAuthorship W2089638752A5078351605 @default.
• W2089638752 hasAuthorship W2089638752A5083678047 @default.
• W2089638752 hasBestOaLocation W20896387521 @default.
• W2089638752 hasConcept C126322002 @default.
• W2089638752 hasConcept C126894567 @default.
• W2089638752 hasConcept C141071460 @default.
• W2089638752 hasConcept C143998085 @default.
• W2089638752 hasConcept C203092338 @default.
• W2089638752 hasConcept C2776364478 @default.
• W2089638752 hasConcept C2776694085 @default.
• W2089638752 hasConcept C2777063308 @default.
• W2089638752 hasConcept C2777478702 @default.
• W2089638752 hasConcept C2778684742 @default.
• W2089638752 hasConcept C2778720950 @default.
• W2089638752 hasConcept C2779050716 @default.
• W2089638752 hasConcept C535046627 @default.
• W2089638752 hasConcept C71924100 @default.
• W2089638752 hasConcept C90924648 @default.
• W2089638752 hasConceptScore W2089638752C126322002 @default.
• W2089638752 hasConceptScore W2089638752C126894567 @default.
• W2089638752 hasConceptScore W2089638752C141071460 @default.
• W2089638752 hasConceptScore W2089638752C143998085 @default.
• W2089638752 hasConceptScore W2089638752C203092338 @default.
• W2089638752 hasConceptScore W2089638752C2776364478 @default.
• W2089638752 hasConceptScore W2089638752C2776694085 @default.
• W2089638752 hasConceptScore W2089638752C2777063308 @default.

• next